REXN Key Statistics, Chart & Performance
The current stock price of REXN is 1.81 null. In the past month the price decreased by -17.35%. In the past year, price increased by 0.56%.
About REXN
Company Profile
REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy.
Company Info
Rexahn Pharmaceuticals
15245 SHADY GROVE ROAD SUITE 455
ROCKVILLE MD 20850
CEO: Douglas J. Swirsky
Phone: 240-268-5300
Rexahn Pharmaceuticals / REXN FAQ
What does REXN do?
REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy.
What is the current price of REXN stock?
The current stock price of REXN is 1.81 null. The price decreased by -3.21% in the last trading session.
Does REXN stock pay dividends?
REXN does not pay a dividend.
How is the ChartMill rating for Rexahn Pharmaceuticals?
REXN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is Rexahn Pharmaceuticals (REXN) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on REXN.
Can you provide the ownership details for REXN stock?
You can find the ownership structure of Rexahn Pharmaceuticals (REXN) on the Ownership tab.
REXN Technical Analysis
REXN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to REXN. REXN may be in some trouble as it scores bad on both profitability and health.
REXN Financial Highlights
Over the last trailing twelve months REXN reported a non-GAAP Earnings per Share(EPS) of -1.4100000000000001. The EPS increased by 25.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -553.95% | ||
| ROA | -72.11% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |